[go: up one dir, main page]

CN104800203A - Novel use of compound - Google Patents

Novel use of compound Download PDF

Info

Publication number
CN104800203A
CN104800203A CN201410043692.8A CN201410043692A CN104800203A CN 104800203 A CN104800203 A CN 104800203A CN 201410043692 A CN201410043692 A CN 201410043692A CN 104800203 A CN104800203 A CN 104800203A
Authority
CN
China
Prior art keywords
compound
group
reserpine
drug
depression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410043692.8A
Other languages
Chinese (zh)
Inventor
闫兴丽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201410043692.8A priority Critical patent/CN104800203A/en
Publication of CN104800203A publication Critical patent/CN104800203A/en
Pending legal-status Critical Current

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention discloses a use of a compound shown in the formula I in preparation of anti-depression drugs. A research proves that the compound can obviously improve reserpinized mouse motion frequency, reversal model mouse temperature decreasing and eye closure conditions, improve mouse central nervous system dysfunction and substantially improve a depression state of a depressive rat.

Description

A kind of novelty teabag of compound
Technical field
The present invention relates to a kind of novelty teabag of compound, be specifically related to the novelty teabag of this compound in preparation treatment is depressed, belong to field of medicaments.
Background technology
Depression is a kind of common affective disorders, and the mental sickness being basic clinical with the remarkable and lasting change of mental state (soar or low), often with corresponding thinking and behavior change.Polytype can be divided into clinically, as endogenous depression, psychogenic depression disease, secondary depression etc.; Symptom centered by depressed, shows as pessimism, and lose interest to daily life, lethargy is depressed, loss of appetite, and suicidal thought or behavior appear in severe patient even repeatedly.The physical and mental health of serious threat people, and extensive damage is caused to family and society.Belong to the category of the disease such as the traditional Chinese medical science " strongly fragrant disease ", " hysteria ", " Bulbus Lilii syndrome ".
Summary of the invention
A kind of compound is the object of the present invention is to provide to prepare the purposes of antidepressant drug.
The object of the invention is to be achieved through the following technical solutions:
A kind ofly preparing the purposes of antidepressant drug such as formula the compound shown in I.
Further, the application in preparation treatment drug-induced depression medicine.
Described drug induccd refers to: reserpine or the depressor similar with reserpine, or comprise reserpine or with the compositions of reserpine with hypotensor; Or, any one of depression can be caused in anti-anaerobism medicine, antitubercular agent, anti-arrhythmic, cardiac tonic, antuepileptic, antiparkinsonism drug, antipyretic analgesic, gastrointestinal function regulating, Psychotolytic, hypnotic, contraceptive.
Described anti-anaerobism medicine is metronidazole; Described antitubercular agent is isoniazid; Described anti-arrhythmic is norpace (disopyramide), propafenone, lignocaine or propranolol; Described cardiac tonic is Folium Digitalis Purpureae; Described antuepileptic is carbamazepine or phenytoin Sodium; Described antiparkinsonism drug is levodopa or Buddha's warrior attendant gastral cavity amine; Described antipyretic analgesic is ibuprofen or indometacin; Described gastrointestinal function regulating is cimetidine or metoclopramide; Described Psychotolytic is chlorpromazine; Described hypnotic is stable.
The compounds of this invention can add the acceptable adjuvant of pharmacy and make the acceptable any conventional dosage form of pharmaceutics, includes but not limited to capsule, tablet, granule, ejection preparation, slow releasing agent, oral liquid or drop pill;
The acceptable adjuvant of described pharmacy comprises: filler, disintegrating agent, lubricant, suspending agent, binding agent, sweeting agent, correctives, antiseptic, substrate etc.Filler comprises: starch, pregelatinized Starch, lactose, mannitol, chitin, microcrystalline Cellulose, sucrose etc.; Disintegrating agent comprises: starch, pregelatinized Starch, microcrystalline Cellulose, carboxymethyl starch sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose etc.; Lubricant comprises: magnesium stearate, sodium lauryl sulphate, Pulvis Talci, silicon dioxide etc.; Suspending agent comprises: polyvinylpyrrolidone, microcrystalline Cellulose, sucrose, agar, hydroxypropyl emthylcellulose etc.; Binding agent comprises, starch slurry, polyvinylpyrrolidone, hydroxypropyl emthylcellulose etc.; Sweeting agent comprises: saccharin sodium, Aspartane, sucrose, cyclamate, enoxolone etc.; Correctives comprises: sweeting agent and various essence; Antiseptic comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its esters, benzalkonium bromide, acetic acid chloroethene are fixed, Folium eucalypti globueli (Eucalyptus globulus Labill.) wet goods; Substrate comprises: PEG6000, PEG4000, insect wax etc.
Experimentation shows, the compound shown in formula I obviously can increase the movable number of times of reserpinization mice, Reversal model mouse temperature declines and closes order situation, improves the situation of the central nervous system function exception of mice; And depression rat spirit depressing state can be improved significantly.
Experimental example 1 Compound I is on the impact of reserpinization mice behavior
1 experiment material
1.1 laboratory animals: ICR mice, body weight 20-22g, male.Herd YANG excess purchased from Beijing gold and test animal cultivation Co., Ltd, animal licence is numbered: SCXK (capital) 2009-0007.
1.2 medicines and reagent
Test medicine: Compound I (being prepared by embodiment 1)
Positive drug: fluoxetine (Patheon France), lot number: 0935A;
Get above medicine appropriate, be dissolved in 0.5%CMC, be made into desired concn;
Fluoxetine dose is 2mg/kg body weight.
Modeling medicine: reserpine injection, 1g/L, Tianjin KingYork Amino Acid Co., Ltd., 1104081;
Reserpine injection normal saline dilution 20 times of rear use, after dilution, concentration is 0.05g/L, and dosage is 0.3mg/kg.
1.3 instruments:
Autonomic activities instrument: MK-ANIMEX, Japan;
MC-108L type electronic clinical thermometer: Omron (Dalian) company limited.
2 experimental techniques
Animal is divided at random: matched group, reserpine model (0.3mg/kg) group, Compound I heavy dose (0.8mg/kg), middle dosage (0.4mg/kg), low dose of (0.2mg/kg) group, fluoxetine (2mg/kg) group.The large, medium and small dosage group of Compound I, fluoxetine group gives respectively: Compound I: 0.8mg/kg, 0.4mg/kg, 0.2mg/kg, fluoxetine: 2mg/kg.Continuous gastric infusion 8d, every day 1 time, matched group gives 0.5%CMC0.2mL/10g.
Other group mice administration subcutaneous injection of reserpine (0.3mg/kg) modelings simultaneously except matched group, control group mice subcutaneous injection normal saline.
2.1 Compound I are on the impact of reserpinization mice autonomic activities
Administration on the 7th 1h after subcutaneous injection of reserpine, be placed in autonomic activities monitor, record animal activity number of times in 4 minutes by mice.
2.2 Compound I are on the impact of reserpinization mouse temperature and catacleisis
Administration on the 8th 1h after subcutaneous injection of reserpine, put into beaker by mice, observe its catacleisis and mark.(standards of grading: eyelid full cut-off 4 points; Close 3/4,3 points; Close 1/2,2 points; Close 1/4,1 point; Entirely open, 0 point).Then thermometer probe is inserted mice anal and be about 1.2cm take temperature.
Date processing: data with represent, adopt SPSS17.0 statistical software to analyze, carry out variance analysis with ANOVA, compare between LSD group, P<0.05 is significant difference.
3 experimental results
3.1 Compound I are on the impact of reserpinization mice autonomic activities
The results are shown in Table 1.
Table 1 Compound I is on the impact of reserpinization mice autonomic activities
Group Dosage (mg/kg) Number of animals (only) Autonomic activities (secondary)
Matched group - 11 68.18±20.97**
Reserpine model group 0.3 12 44.58±21.79
The heavy dose of group of Compound I 0.8 12 81.75±17.79**
Dosage group in Compound I 0.4 12 60.42±18.83*
Compound I small dose group 0.2 12 47.42±12.41
Fluoxetine group 2 12 69.08±1.79**
Note: compare with model group, * p<0.05, * * p<0.01
From table 1, compare with matched group, reserpinization mice autonomic activities significantly declines (P<0.01); Compare with model group, Compound I is heavy dose of, fluoxetine group significantly can increase mice autonomic activities number of times (P<0.01), and in Compound I, dosage group obviously can increase mice autonomic activities number of times (P<0.05); Compound I small dose group has the trend increasing the movable number of times of mice, but there was no significant difference (P>0.05).
3.2 Compound I are on the impact of reserpinization mouse temperature, catacleisis
The results are shown in Table 2.
Table 2 Compound I is on the impact of reserpinization mouse temperature, catacleisis
Group Dosage (mg/kg) Animal (only) Anus temperature (DEG C) Eyelid is marked
Matched group - 11 37.87±0.52** 1.36±0.92**
Reserpine model group - 12 35.43±0.91 2.92±0.90
The heavy dose of group of Compound I 0.8 12 36.49±0.67** 1.42±1.16**
Dosage group in Compound I 0.4 12 37.02±0.52** 1.83±0.94**
Compound I small dose group 0.2 12 36.90±0.36** 2.25±0.96
Fluoxetine group 2 12 36.60±0.09** 1.54±1.44**
Note: compare with model group, * p<0.05, * * p<0.01
Reserpine chronic administration can cause mouse temperature and decline, closes one's eyes.As shown in Table 2, each group of Compound I, fluoxetine group all have remarkable antagonism (P<0.01) to temperature decline caused by reserpine chronic administration; Matched group, Compound I heavy dose, middle dosage group, fluoxetine group significantly can reverse reserpinization mice eye closing situation (P<0.01).
Experimental example 2 Compound I is on the impact of rat nervous system
1 experiment material
1.1 laboratory animals: SD rat, body weight 140-160g, male.Beijing Vital River Experimental Animals Technology Co., Ltd. provides, and animal licence is numbered: SCXK (capital) 2012-0001.Animal is in (20-24) DEG C, and in the environment of humidity 60%-70%, 12h light and shade, adaptability starts experiment after raising 3 days.
1.2 medicines and reagent
Test medicine: the heavy dose of dosage of Compound I is 0.6mg/kg, and middle dosing amount is 0.3mg/kg, and low dose of dosage is 0.15mg/kg body weight.Gastric infusion, administration volume is 1ml/100g body weight.
Positive drug: fluoxetine hydrochloride capsules: Li Lai Suzhou pharmaceutical Co. Ltd, lot number: 2061A, 2072A; Pinaverium Bromide Tablets: French Su Wei pharmacy, lot number: 626683,627414.
Get appropriate above medicine, be dissolved in distilled water the suspension making desired concn.Fluoxetine dosage is 2.5mg/kg body weight, and pinaverium bromide dosage is 25mg/kg.Gastric infusion, administration volume 1ml/100g body weight.
Other reagent: sucrose, Chemical Reagent Co., Ltd., Sinopharm Group, lot number: 20120604.
2 chronic stresses cause the foundation of depression rat model
SD male rat, is divided at random: the large, medium and small dosage group (0.6mg/kg, 0.3mg/kg, 0.15mg/kg) of Normal group, depression model group, pinaverium bromide group (25mg/kg), fluoxetine group (2.5mg/kg), Compound I.Rat every cage orphan of model group and administration group supports, and in addition chronic unpredictable sexual stimulus.Chronic stress comprises: prohibit water, fasting, put upside down round the clock, cold stimulation, thermostimulation, induced pain, actuating.7 kinds of stimulating factor random arrangements, every day is a kind of, and often kind of stimulation can not occur continuously, makes animal can not expect the generation stimulated.Each group of Compound I and each treated animal modeling of positive drug simultaneously every day gastric infusion.Matched group and model group give gavage distilled water.
Stress operational approach:
Chronic stress:
Prohibit water: within 24 hours, cut off the water supply.
Fasting: 24 hours jejunitas.
Put upside down round the clock: when morning 8, animal is put into darkroom, do not turn on light and make animal be in dark state; To late 8 time darkroom lamp is opened, make animal be in illumination conditions, to next day early 8 time take out.
Cold stimulation: animal is placed in the bucket (depth of water 15cm) filling 4 DEG C of frozen water, takes out after 5min.
Thermostimulation: SHH-500ZSD animal experiment box animal being placed in 45 DEG C, takes out after 5min.
Induced pain: clamp rat apart from root of the tail 3cm place with mosquito forceps (wrapping up in Cotton Gossypii outward), continues folder tail 1min.
Braking: animal is placed in constraint cage, its extremity head can not arbitrarily be swung, first time braking constraint 5 hours, the later time increases progressively 1h successively.
3 experimental techniques
3.1 liquid-consumed experiments
Sucrose solution well can detect the ergasia state of depression model animal partially addicted to degree experiment.Mostly adopting sucrose solution partially addicted to spending percentage rate as the effective objective indicator measuring anhedonia at present, judging anxiety or the depressive state of depressed animal central nervous systems.
The training of experiment advance action thing sucrose diseases caused by retention of fluid.Every noise, in quiet room, 2 water bottles placed by every cage simultaneously, first 24 hours, two bottles are all equipped with 1% sucrose water.Subsequently 24 hours, one bottled had 1% sucrose water, a bottled pure water.Fasting prohibited water after 24 hours, carried out the basic sucrose solution/pure water consumption experiment of animal.Give every rat fixed measured two bottles of water in advance: one bottle of 1% sucrose water, one bottle of pure water simultaneously.After 4h, take two bottles away and weigh, calculating the sucrose solution of animal partially addicted to degree.Before and after mensuration modeling, sucrose water is partially addicted to the change of degree.Sucrose solution is partially addicted to degree (%)=(sucrose solution consumption (g)/(sucrose solution consumption (g)+pure water consumption (g)) × 100%.
3.2 Open field test (open-field test)
Open field test can be used to " excitement " or " depression " state of test animal central nervous system, and wherein horizontal score reflects the exploratory behavior of reflection animal, and namely active degree, moves both vertically, reflect the curious degree of animal to fresh ambient.
Spacious case height 40cm used, length and width are 80cm, and perisporium is black, and white ground black line is divided into 25 pieces of area equation, test and carry out in the quiet room of dark.
Single rat is placed in clean spacious case central authorities, measure animal travels ground square number as horizontal movement score (more than 3 pawls striding into), lattice remember 1 point; With number of times of standing for the score that moves both vertically (two forelimbs are liftoff 1 centimetre), stand and once remember 1 point.Every animal only once measures at every turn, each 5 minutes.Animal excrements ethanol is needed to remove totally after each test. measure the change of animal horizontal movement score and the score that moves both vertically before and after modeling.
4 statistical method
Data with represent, adopt SPSS17.0 statistical software to analyze.Multiple sample average compares with one factor analysis of variance (One-way ANOVA).Wherein the neat person of variance compares with between LSD method group, and heterogeneity of variance person adopts between Dunnett's T3 method group and compares.P<0.05 is that difference has significant difference.
5 experimental results
5.1 Compound I on rat model sucrose solution partially addicted to degree impact
The results are shown in Table 3-4.
Before table 3 modeling, 20 days time Compound I on depression rat sucrose solution partially addicted to degree impact
During table 4 modeling 42 days, 63 days Compound I on depression rat sucrose solution partially addicted to the impact of degree
Compare with model group: P<0.01**, P<0.05*
From table 3,4, before modeling, the sucrose solution of each group rat does not have obvious significant difference (P>0.05) addicted to degree partially;
During modeling 21 days, each group rat sucrose solution does not have obvious significant difference (P>0.05) addicted to degree partially, and model group rats sucrose solution has downward trend addicted to degree partially, and the hints model group rat mental status declines.Positive drug group and each dosage group of Compound I are also all improved sucrose solution partially addicted to the trend of degree.
During modeling 42 days, the sucrose solution of model group rats reduces (P<0.05) addicted to degree partially, illustrates that the state of anxiety, depression has appearred in model group rats.Positive drug pinaverium bromide and fluoxetine all can improve rat model sucrose solution partially addicted to degree (P<0.05); Compound I low dose (0.15mg/kg) can improve rat model sucrose solution partially addicted to degree (P<0.05).
During modeling 63 days, model group rats sucrose solution significantly reduces (P<0.01) addicted to degree partially, and point out along with stress the prolongation of time, the depressive state of rat model be more serious.Positive drug pinaverium bromide and fluoxetine all significantly can increase the sucrose solution of rat model partially addicted to degree (P<0.01).The large, medium and small dosage of Compound I all can improve rat model sucrose solution partially addicted to degree, and wherein Compound I heavy dose (0.6mg/kg) and low dose of (0.15mg/kg) significantly can increase the sucrose solution of rat model partially addicted to degree (P<0.01).
5.2 Compound I open the impact of case motion to rat model
5.2.1 Compound I causes the impact of the horizontal score of depression model rat on chronic stress
The results are shown in Table 5.
Table 5 Compound I causes the impact of the horizontal score of depression model rat to chronic stress
Compare with model group: * * p<0.01; * p<0.05
As shown in Table 5, when modeling 12 days, compare with matched group, the horizontal score of model group animal increases; Compare with model group, Compound I big or middle dosage group and positive drug pinaverium bromide and fluoxetine all can lower the horizontal score of animal pattern, and effect obviously (P<0.05);
Modeling the 33rd day, the horizontal score no difference of science of statistics of each group;
Modeling the 55th day, compare with matched group, the horizontal score of model group animal reduces; Compare with model group, Compound I large, medium and small dosage group and positive drug fluoxetine can increase the horizontal score of animal pattern.
5.2.2 Compound I causes the impact of the vertical score of depression model rat on chronic stress
The results are shown in Table 6.
Table 6 Compound I causes the impact of the vertical score of depression model rat to chronic stress
Compare with model group: * * p<0.01; * p<0.05
As shown in Table 6, when modeling 12 days, compare with matched group, the vertical score of model group animal increases; Compare with model group, Compound I large, medium and small dosage group and positive drug pinaverium bromide all can lower the vertical score of animal pattern with fluoxetine, and the big or middle dosage effect of Compound I obviously (P<0.05);
Modeling the 33rd day, the vertical score no difference of science of statistics of each group; Modeling the 55th day, compare with matched group, the vertical score of model group animal significantly reduces (P<0.05); Compare with model group, Compound I large, medium and small dosage group and positive drug pinaverium bromide significantly can increase the vertical score (P<0.05) of animal pattern with fluoxetine.
Experimental example 3 Compound I is on the impact of 5-HT in depression model rat brain
1 experiment material
1.1 laboratory animals: SD rat, body weight 140-160g, male.Beijing Vital River Experimental Animals Technology Co., Ltd. provides, and animal licence is numbered: SCXK (capital) 2012-0001.Animal is in (20-24) DEG C, and in the environment of humidity 60%-70%, 12h light and shade, adaptability starts experiment after raising 3 days.
1.2 medicines and reagent
Test medicine: the heavy dose of dosage of Compound I is 0.6mg/kg, and middle dosing amount is 0.3mg/kg, and low dose of dosage is 0.15mg/kg body weight.Gastric infusion, administration volume is 1ml/100g body weight.
Positive drug: fluoxetine hydrochloride capsules: Li Lai Suzhou pharmaceutical Co. Ltd, lot number: 2061A, 2072A; Pinaverium Bromide Tablets: French Su Wei pharmacy, lot number: 626683,627414.
Get appropriate above medicine, be dissolved in distilled water the suspension making desired concn.Fluoxetine dosage is 2.5mg/kg body weight, and pinaverium bromide dosage is 25mg/kg.Gastric infusion, administration volume 1ml/100g body weight.
2 experimental techniques
2.1 chronic stresses cause the foundation (with experimental example 2) of depression rat model
2.2 detect each group of neuronic expression of rat 5-HT and distribution: get rat brain Hippocampus (position that Paxinos rat brain location collection of illustrative plates is determined), adopt the method for SABC, detect the neuronic expression of 5-HT and distribution situation in periphery and maincenter, image after picked-up labelling, carries out quantitative analysis with IPP6.0 software.
3 experimental results
In model group rats Hippocampus, 5-HT expresses significantly reduction (P<0.01) as shown in Table 7, and Compound I significantly can raise the 5-HT in Hippocampus.
Table 7 Compound I is on the impact of 5-HT in depression model rat brain
Group N/ only Dosage (mg/kg) 5-HT positivity index
Blank 9 -- 0.030±0.007**
Model 9 -- 0.017±0.005
The heavy dose of group of Compound I 9 0.6 0.024±0.003*
Dosage group in Compound I 9 0.3 0.023±0.005*
Compound I small dose group 9 0.15 0.021±0.005
Pinaverium bromide 9 25 0.024±0.004*
Fluoxetine 9 2.5 0.023±0.002*
Detailed description of the invention
The preparation of embodiment 1 the compounds of this invention
1 instrument, reagent and medical material
Instrument: RE-52A rotary evaporator (Shanghai Yarong Biochemical Instrument Plant); The multiplex vacuum pump of SHB-III circulating water type (Zhengzhou Greatwall Scientific Industrial & Trading Co., Ltd.); KQ-S00DE type numerical control ultrasonic cleaner (city of Kunshan has children outside the state plan Instrument Ltd.); DS electric heating three water-bath (Beijing Medical Equipment Plant); Sartorious BT25S type 1/100000 electronic analytical balance (Beijing Sai Duolisi Instrument Ltd.); ZF-I type ultraviolet analysis instrument for three purposed (Shanghai Gu Cun electric light instrument plant); WH-43 type Constant Temp. Oven (Tianjin Stettlen Instrument Ltd.); Bruker-Avance VNS-600 type nuclear magnetic resonance analyser (CAMAG company of Switzerland).
Reagent: AB-8 type macroporous adsorbent resin (Tianjin Nankai university chemical plant); Column chromatography silica gel (200 ~ 300 orders, Haiyang Chemical Plant, Qingdao), silica gel G prefabricated thin laminate (20 × 20cm) (Haiyang Chemical Plant, Qingdao); Other reagent are analytical pure.
Medical material: experiment purchased from Yunnan, is accredited as Valerianaceae valeriana Rhizoma valerianae latifoliae through Beijing University of Chinese Medicine professor Shi Jinli with Rhizoma valerianae latifoliae medical material; Pentamethylene .-pyrans-7-formaldehyde, 4-ethoxyl methyl reference substance is made by oneself.
The extraction and isolation of 2 chemical compositions
The extraction of 2.1 chemical compositions
Take Rhizoma valerianae latifoliae medical material 8kg and be ground into coarse powder, add the soak with ethanol 1h of 12 times amount 80%, heating and refluxing extraction twice, merge extractive liquid, decompression recycling ethanol; Concentrated solution thin up filters, and supernatant crosses AB-8 macroporous adsorbent resin, with 30% ethanol remove impurity, then uses 90% ethanol elution, collects eluent, decompression recycling ethanol, and the dry 24h of reduced vacuum, to constant weight, obtains the dry cream of 80.5g Rhizoma valerianae latifoliae extract, for subsequent use.
The separation of 2.2 effective sites
By silicagel column on the dry cream of 80.5g Rhizoma valerianae latifoliae extract, adopt petroleum ether-ethyl acetate gradient elution, collect petroleum ether-ethyl acetate (9:1) eluent, be numbered Fr2-60; Merged by Fr.52-55, decompression and solvent recovery, to dry, with dissolve with methanol, crosses Sephadex LH-20 gel column, methanol-eluted fractions, collects eluent, carries out inspection and knows, merge the fraction of identical principal spot with GF254 silica gel plate, 1. decompression and solvent recovery, with Gossypol recrystallized from chloroform, obtain yellow powder.2. decompression and solvent recovery after being merged by Fr.56-59, obtain yellow powder with petroleum ether recrystallization.Merge 1. with 2., be the compound of formula I structure.
3 compound structure qualifications
Yellow powder, displaing yellow fluorescence under uviol lamp.Dissolve in chloroform, methanol.Signals assignment is as follows:
1H-NMR(500MHz，MeOH)δ：9.94(1H，s，H-10)，9.21(1H，s，H-1)，8.20(1H，s，H-3)，7.96(1H，d，J=3.2Hz，H-7)，6.69(1H，d，J=3.2Hz，H-6)，5.30(2H，s，H-11)，2.07(3H，s，-OCOCH3)。
13C-NMR(75MHz，MeOH)δ：185.6(C-10)，171.5(-OCOCH3)，152.2(C-1)，147.2(C-7)，144.1(C-3)，134.8(C-5)，126.6(C-8)，124.5(C-9)，121.3(C-4)，110.9(C-6)，61.6(C-11)，21.3(-OCOCH3)。Spectral data is contrasted with existing document, determines that structural formula is:

Claims (5)

1. preparing the application of antidepressant drug such as formula the compound shown in I for one kind;
2. apply as claimed in claim 1, it is characterized in that treating drug induced depression.
3. apply as claimed in claim 2, described drug induccd refers to: reserpine or the depressor similar with reserpine, or comprise reserpine or with the compositions of reserpine with hypotensor; Or, any one of depression can be caused in anti-anaerobism medicine, antitubercular agent, anti-arrhythmic, cardiac tonic, antuepileptic, antiparkinsonism drug, antipyretic analgesic, gastrointestinal function regulating, Psychotolytic, hypnotic, contraceptive.
4. apply as claimed in claim 3, described anti-anaerobism medicine is metronidazole; Described antitubercular agent is isoniazid; Described anti-arrhythmic is norpace (disopyramide), propafenone, lignocaine or propranolol; Described cardiac tonic is Folium Digitalis Purpureae; Described antuepileptic is carbamazepine or phenytoin Sodium; Described antiparkinsonism drug is levodopa or Buddha's warrior attendant gastral cavity amine; Described antipyretic analgesic is ibuprofen or indometacin; Described gastrointestinal function regulating is cimetidine or metoclopramide; Described Psychotolytic is chlorpromazine; Described hypnotic is stable.
5. the application as described in as arbitrary in claim 1-4, is characterized in that Compound I can add the acceptable adjuvant of pharmacy and make capsule, tablet, granule, ejection preparation, slow releasing agent, oral liquid or drop pill.
CN201410043692.8A 2014-01-28 2014-01-28 Novel use of compound Pending CN104800203A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410043692.8A CN104800203A (en) 2014-01-28 2014-01-28 Novel use of compound

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410043692.8A CN104800203A (en) 2014-01-28 2014-01-28 Novel use of compound

Publications (1)

Publication Number Publication Date
CN104800203A true CN104800203A (en) 2015-07-29

Family

ID=53685700

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410043692.8A Pending CN104800203A (en) 2014-01-28 2014-01-28 Novel use of compound

Country Status (1)

Country Link
CN (1) CN104800203A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116270643A (en) * 2023-04-19 2023-06-23 中山大学 Animal model for chronic depression, medicine screening method and application

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101569621A (en) * 2008-04-30 2009-11-04 肖丹 Application of iridoid compound in preparing medicament for treating benign prostatic hyperplasia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101569621A (en) * 2008-04-30 2009-11-04 肖丹 Application of iridoid compound in preparing medicament for treating benign prostatic hyperplasia

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
宋歌等: "蜘蛛香中环烯醚萜类成分大孔树脂纯化工艺的研究", 《北京中医药大学学报》 *
张振学等: "药用植物缬草的生物活性研究进展与开发", 《沈阳药科大学学报》 *
闫兴丽: "蜘蛛香环烯醚萜对肠易激综合征的治疗作用及机理探讨", 《中国博士学位论文全文数据库 医药卫生科技辑》 *
黄宝康等: "缬草镇静催眠的物质基础", 《药学服务与研究》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116270643A (en) * 2023-04-19 2023-06-23 中山大学 Animal model for chronic depression, medicine screening method and application

Similar Documents

Publication Publication Date Title
WO2010133015A1 (en) Pharmaceutical composition for treating depression and preparative method and use thereof
CN102014931B (en) Use and preparation of paeoniflorin and the composition thereof
WO2011047576A1 (en) Use of albiflorin for anti-depression
CN103479963A (en) Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof
CN102526141B (en) Pterocephalus hookeri heck total iridoid glycoside extract and preparation method and application thereof
CN104940479A (en) TCM composition for treating AD diseases
CN100438876C (en) Use of 20(S)-protopanoxadiol in preparation of antidepressant medicine
CN101327289B (en) New application of day lily and total flavonoids of day lily
CN101590065A (en) Application of Siberia polygala sugar A1, Siberia polygala sugar A5 and tenuifoliside A in preparation of products for treating depression
CN103191198A (en) Rhizoma corydalis extract as well as preparation method and use thereof
CN102283910B (en) Chinese medicinal composition with anti-depression effect and preparation and preparation method thereof
CN104800203A (en) Novel use of compound
Akhter et al. Investigation of in vivo analgesic and anti-inflammatory activities of methanol extracts of Phyllanthus reticulatus and Mimosa pigra
CN104055812B (en) A kind of composition and preparation method and purposes with antidepressant effect
CN100478000C (en) Application of valeriana wallichii and its extract in preparation of medicine for treating anxiety neurosis
CN104095938B (en) A kind of Mongolian medicinal preparation of Cure of depression
CN107753630A (en) The pharmaceutical composition and preparation method of a kind for the treatment of of insomnia patients
CN101904894A (en) Application of lamiophlomis rotate total glycosides to preparing medicines
CN1857337B (en) Use of patrinia herb and its extract in preparing medicine for treating prostatic hyperplasia
CN104189346A (en) New pharmaceutical composition capable of promoting gastrointestinal motility and preparation method thereof
CN100545163C (en) A traditional Chinese medicine active ingredient compound for preventing and treating senile dementia and its preparation and application
CN102716275A (en) Detection method of anti-anxiety pharmaceutical composition
CN104800202A (en) Novel use of compound
CN101485770A (en) Medicament composing prescription for treating leukoderma and technique for preparing the same
CN100522195C (en) A pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, its preparation method and application

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150729